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Abstract
Focal point-by-point radiofrequency catheter ablation has shown considerable success in the 
treatment  of  paroxysmal  atrial  fibrillation.  However,  it  is  not  without  limitations.  Recent 
clinical and preclinical studies have demonstrated that cryothermal ablation using a balloon 
catheter (Artic Front©, Medtronic CryoCath LP) provides an effective alternative strategy to 
treating atrial fibrillation. The objective of this article is to review efficacy and safety data 
surrounding cryoballoon ablation for paroxysmal and persistent atrial fibrillation. In addition, 
a  practical  step-by-step  approach  to  cryoballoon  ablation  is  presented,  while  highlighting 
relevant  literature  regarding:  1)  the  rationale  for  adjunctive  imaging,  2)  selection  of  an 
appropriate  cryoballoon  size,  3)  predictors  of  efficacy,  4)  advanced  trouble-shooting 
techniques, and 5) strategies to reduce procedural complications, such as phrenic nerve palsy. 
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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia.  It accounts for the 
majority  of arrhythmia-related  emergency room visits  and hospital  admissions,[1-3] and is 
associated with reductions in quality of life, functional status, cardiac performance, and overall 
survival.[1] Catheter ablation, which is centered on electrical isolation of triggering foci within 
the pulmonary veins (PV) through circumferential lesions around PV ostia, has been shown to 
result in sustained improvements in quality of life, decreased hospitalizations and, potentially, 
improved  survival.[4-6]                                                        
Radiofrequency  (RF)  catheter  ablation  has  shown  considerable  success  in  treating 
symptomatic  AF,  particularly  in  comparison to  anti-arrhythmic  drugs  [7,8].  Unfortunately, 
major complications including thromboembolism, cardiac perforation, and injury to adjacent 
structures are not infrequently observed [2,3,7,9,10]. Further, the procedure is complex, time-
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consuming  and  highly  dependent  on  operator  competency  given  the  inherent  difficulties 
associated with creating contiguous curvilinear lesions with a technique originally developed 
for  focal  ablation.  As  such,  considerable  effort  has  been  directed  towards  developing 
technologies specifically for PV isolation (PVI) as a means to achieve safer and more effective 
PVI that is less reliant on operator dexterity.  Recently clinical and preclinical studies have 
demonstrated  that  cryothermal  ablation  using a  balloon  catheter  (Artic  Front©,  Medtronic 
CryoCath  LP,  Kirkland,  Canada)  is  an  effective  alternative  treatment  for  AF.         
Efficacy  of  Cryoballoon  Ablation                                      
To  date  over  20,000  cryoballoon-based  PV  ablation  procedures  have  been  performed 
worldwide. In a recent systematic review and meta-analysis, we reported the cumulative early 
experience with cryoballoon-based ablation (CBA).[11] CBA resulted in a high procedural 
success rate (>98% of patients achieving complete PVI) and 1-year freedom from recurrent 
AF (single cryoballoon procedure off anti-arrhythmic drugs 1-year success of 60%; 73% if a 
3-month blacking period was included) [11,12]. In comparison, the longer-term freedom from 
recurrent AF after RF catheter ablation has been reported to be 50% to 64% after a mean 
follow-up of 14 months in the meta-analysis by Calkins et al. and 39.8±5.1% at 1 year in the 
prospective long-term cohort study by Weerasooriya et al.[7,13] Thus, the early experience 
suggests that cryoballoon ablation is efficacious for the maintenance of sinus rhythm at 1 year 
in  patients  with  paroxysmal  AF.                                       
When  compared  to  other  rhythm control  strategies,  CBA has  performed  favourably.  (See 
Table 1) The first randomized trial  comparing AAD therapy and cryoballoon ablation,  the 
Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP-AF) trial, enrolled 245 patients 
with paroxysmal AF and randomized them (2:1) to cryoballoon-based PV isolation (n=163) or 
to AAD therapy (n=82).[14] The mean age of participants was 57 years, and those enrolled 
had  already  failed  an  average  of  1.2  AADs.  Balloon-only  PVI  was  realised  in  90.8% of 
participants,  with  an  overall  procedural  success  (≥3  PVs  isolated)  of  98.2%  when  focal 
cryoablation was added. Nineteen percent of patients required a repeat procedure within the 3-
month blanking period. At 12 months of follow-up, 69.9% of the cryoballoon group (114/163) 
vs. 7.3% of the AAD group (6/82) were free of recurrent AF (p<0.001). Moreover, there was a 
statistically significant improvement in symptoms and quality of life in the cryoablation group. 
For all quality-of-life metrics, the improvement was greater in the cryoballoon group when 
compared to the AAD group.
Likewise, in comparison to other contemporary AF ablation technologies, CBA has performed 
favourably.  In  general,  CBA is  associated  with  procedure  and  fluoroscopy times  that  are 
somewhat longer than duty-cycled multi-electrode RF ablation but shorter than conventional 
RF ablation.[15-19]  Despite  these procedural  differences,  efficacy outcomes  at  all  of  time 
points sampled did not differ between CBA and conventional,  magnetic guided, and duty-
cycled  multi-electrode  RF  ablation.  [15-19,20]                                   
Safety  of  Cryoballoon  Ablation                                            
Major complications have been reported in approximately 5-6% of patients undergoing RF 
ablation  for  AF  [7,9,10].  The  rate  of  acute  procedural  complications  reported  with 
cryoballoon-based ablation (CBA) is relatively low (<3-5%) and compares favourably with 
irrigated RF and duty-cycled multi-electrode RF ablation [7,9,10,21]. With CBA, the reported 
rate of peri-procedural stroke or transient ischemic attack (TIA) is 0.3%, cardiac tamponade 
0.6%,  and  groin  complications  1.8%.  In  comparison,  corresponding reported  complication 
rates with RF ablation are 0.3-0.9% for stroke or TIA, 0.8-1.3% for cardiac tamponade, and 1-
1.5%  for  groin  complications.[11]  Longer-term  complications  such  as  symptomatic  PV 
stenosis and esophageal injury occurred infrequently with CBA (0.17% for symptomatic PV 
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stenosis and a 0% incidence of atrial-oesophageal fistula).[11] Given the inclusion of patients 
early in the operators' learning curves, it is possible that the rate of complications with CBA 
will decrease further as operators gain experience.
Table 1: Studies Comparing Cryoballoon-Based Ablation To Other Rhythm Control Methods
AAD - Antiarrhythmic drugs; Magnet - Magnetic-assisted RF; MESH - Mesh Ablator catheter; NR - Not 
reported; NS - Not significant; PVAC - duty-cycled multi-electrode ablation; RF - convention radiofrequency 
catheter ablation
While  the  global  complication  rate  with  CBA  appears  comparable  to  conventional  RF 
ablation, three complications merit further discussion. Initially described in the early animal 
studies by Sarabanda et al., phrenic nerve palsy (PNP) has proven to be the most frequently  
observed  complication  with  CBA,  occurring  in  approximately  6%  of  clinical  procedures 
(range 3-11%) [11,22,23]. While PNP can be observed after AF ablation regardless of the 
energy  source,  it  occurs  disproportionately  more  frequently  with  balloon-based  ablation 
technologies when compared to conventional RF ablation [7,9,10]. Fortunately, despite PNP 
being a relatively common occurrence, the majority of cases are transient with <0.4% of PNPs 
persisting greater  than one year.[11] However,  while  persistent  PNP is  rare,  the incidence 
appears to be approximately twice that reported with conventional RF ablation (0.17%).[9]
The  most  commonly  employed  preventative  measure  is  the  use  of  continuous  abdominal 
palpation during phrenic nerve pacing from a catheter placed in the superior vena cava cranial 
to the right-sided PVs. However, despite early interruption of ablation with the perceived onset 
of less vigorous diaphragmatic contractions, PNP continues to be observed. As such, efforts 
have been directed towards determining a more effective method for detecting early changes to 
the phrenic nerve. One such approach involving the use of diaphragmatic electromyography 
(EMG)  has  recently  been  published.[22]  During  phrenic  nerve  pacing,  a  reproducible 
supramaximal  diaphragmatic  compound  motor  action  potential  (CMAP)  can  be  reliably 
recorded,  providing valuable  information  about  phrenic  nerve function.  In a recent  animal 
study,  it  was  demonstrated  that  a  30%  reduction  in  CMAP  amplitude  reliably  predicted 
impending  hemidiaphragmatic  paralysis  (presaging  diaphragmatic  paralysis  by  abdominal 
palpation by 31 ± 23 seconds).[22]  The first clinical application of this technique has also 
been  reported.[24]                                     
The second complication that warrants a more in depth discussion is that of PV stenosis, as its 
incidence with CBA is somewhat controversial. Prior to the recent STOP-AF trial, PV stenosis 
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was  thought  to  be  non-existent  after  CBA.  While  multiple  studies  employing  the  use  of 
systematic screening reported no PV stenosis (0/550 patients), the landmark STOP-AF trial 
noted a 3.07% (7/228 patients) incidence of radiographic PV stenosis [14,25-32]. It is most 
likely that this incongruity reflects differences in criteria to define significant PV stenosis. In 
the AF ablation literature,  PV stenosis is most commonly defined on the basis of diameter 
measurements  (typically  as  a  reduction  in  PV diameter  >70%).[8]  In  contrast,  STOP-AF 
defined  PV  stenosis  as  a  >75%  reduction  in  cross-sectional  area  from  baseline,  which 
corresponds to a 50% reduction in PV diameter.[14] As such, this more liberal definition may 
represent a relative overestimate of the rate of PV stenosis and limits direct comparisons to 
other  studies.  Even  so,  when  the  results  of  STOP-AF  were  combined  with  other  studies 
employing systematic screening with non-invasive imaging, the incidence of radiographic PV 
stenosis was 0.90% (7/773 procedures), which is approximately half the rate observed in a 
large meta-analysis of conventional AF ablation with RF [7,25-32]. Reassuringly, the rate of 
symptomatic  PV  stenosis  or  PV  stenosis  requiring  intervention  was  low  (0.17%)  and 
comparable to that  observed with RF (0.1-0.3%) [7,9,10].                                
The  final  complication  that  warrants  a  detailed  discussion  is  that  of  systemic 
thromboembolism.  Cerebral  ischemic  events  are  a  recognized  complication  of  left  atrial 
catheter ablation. In the recent systematic review of CBA, the incidence of thromboembolic 
complications,  including  peri-procedural  stroke  or  TIA,  was  0.32%,  which  compares 
favourably to conventional RF ablation (0.3-0.94%) [7,9,10].                               
Recognising that not all embolic cerebral events lead to clinical symptomatology, a series of 
studies recently examined signs of subclinical disease in an attempt to further delineate the risk 
of  systemic  thromboembolism after  AF ablation.  Sauren  et  al.  examined  the  incidence  of 
cerebral microembolic signals (MES) as a surrogate for neurological impairment and stroke in 
30  patients  undergoing  percutaneous  endocardial  AF  ablation:  10  patients  undergoing 
segmental PVI using a 4-mm conventional (non-irrigated) RF ablation catheter, 10 patients 
undergoing segmental PVI using a 4-mm irrigated-tip RF catheter, and 10 patients undergoing 
circumferential  PVI  with  CBA.[33]  In  this  small  study,  the  authors  demonstrated  a 
significantly lower incidence of MES in the middle cerebral arteries with CBA and irrigated 
RF  catheters  when  compared  to  conventional  non-irrigated  RF  (935±463  and  1,404±981 
versus 3,908±2816 total MES respectively). Similarly, two recent studies comprising a total of 
182 patients compared the incidence of silent cerebral ischemic lesions after PV isolation with 
duty-cycled multi-electrode ablation, conventional irrigated-tip RF ablation, and CBA. In both 
studies the incidence of new silent cerebral ischemic lesions, which have been associated with 
neurocognitive  decline,  was  found to  be  significantly  higher  with  multi-electrode  ablation 
(37.5-38.9%) when compared to irrigated RF (7.4-8.3%) or CBA (4.3-5.6; overall P=0.008 for 
Siklody et al,  and overall  P=0.002 for Gaita et al.) [34,35].                                
How  to  Perform  Cryoballoon  Ablation                                  
Patient  Selection                                   
In current practice, cryoballoon-based AF ablation is reserved for patients undergoing their 
first left atrial ablation for drug-refractory symptomatic paroxysmal AF or early persistent AF. 
While over 20,000 cryoballoon procedures have been performed worldwide, the vast majority 
of  patients  undergoing the procedure have had paroxysmal AF.                          
Left  Atrial  Access                                              
The  ablation  procedure  is  commenced  by  gaining  left  atrial  access  using  a  modified 
Brockenbrough technique and standard transseptal sheath [typically SL0, SL1 or SR0]. It is 
important to ensure that transseptal puncture used for cryoballoon ablation is located in a low 
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anterior position within the membranous septum. Punctures in a more posterior position or 
within the muscular septum limit the manoeuvrability of the cryoballoon-FlexCath apparatus, 
potentially  leading  to  technical  challenges.                                     
Early  in  our  experience,  we evaluated  PV potentials  (PVPs)  though the  introduction  of  a 
conventional diagnostic spiral catheter through a second more posteriorly located transseptal 
puncture. Recently, we modified our technique to perform only a single transseptal puncture. 
Evaluation of PVPs is now performed through the use of a small calibre 15 or 20-mm diameter 
circular  mapping  catheter  introduced  into  the  central  lumen  of  the  cryoballoon  catheter 
(Achieve  catheter;  Medtronic;  Minneapolis,  MN).  The  Achieve  catheter  serves  the  dual 
purpose of acting as guide wire, as well as providing real-time verification of PVI during the 
freezing  cycle,  a  period  during  which  the  placement  of  a  conventional  diagnostic  spiral 
catheter is precluded by cryoballoon-induced PV occlusion. A third possible approach, one 
that we do not advocate due to additional risks that we consider unnecessary, is to perform a 
single transseptal puncture and serially exchange the cryoballoon catheter for a conventional 
spiral catheter. It should be noted that none of these approaches have been demonstrated to 
positively or negatively effect long-term outcomes and, as such, the decision to perform 1 or 2 
transseptal  punctures is  based on physician preference.                                   
Once left atrial access is obtained, a heparin bolus and subsequent infusion are commenced to 
target activated clotting times of 300 seconds. At the operator's discretion, selective or non-
selective pulmonary venography is performed in the antero-posterior projection using a pigtail, 
multipurpose (MP), or National Institute of Health (NIH) catheter to delineate PV anatomy. 
Thereafter, a 300-cm 0.035-inch J-tipped guide wire is positioned in the left superior PV and 
the standard transseptal  sheath is exchanged over the wire for a 12-Fr deflectable delivery 
sheath (15-Fr outer diameter; FlexCath, Medtronic, Minneapolis, MN).                                    
The  Use  Of  Adjunctive  Imaging                                               
The use of adjunctive pre-procedural and intra-procedural imaging has remained a matter of 
physician preference. Although contentious, there are some reports suggesting that atypical PV 
anatomy such as common PV ostia may influence longer-term efficacy [18,36]. Kubala et al.  
evaluated PV anatomic patterns in 118 consecutive patients with drug refractory paroxysmal 
(72%) or persistent (28%) AF [36]. The authors demonstrated that the presence of a normal 
PV pattern  is  associated  with  fewer  recurrences  of  AF at  13  months  of  follow-up,  when 
compared to patients with left common ostia (67% vs. 50%, P = 0.02). The authors postulated 
that this difference might represent increased difficulty in obtaining circumferential lesions in 
the common ostia due to larger ostial diameters, an atypical ostial circumferential geometry, 
and/or a larger border zone between PV tissue and atrial myocardium in comparison to non-
common  PV  ostia.  In  contrast,  Sorgente  et  al.  found  no  difference  in  the  degree  of  PV 
occlusion or longer-term efficacy endpoints between patients with a left common ostium and 
those with normal  branching of left  PVs [18].  Given the conflicting  reports  regarding the 
influence of atypical PV anatomy on longer-term efficacy outcomes, we do not consider the 
presence of common PV ostia to contraindicate CBA [18].                                     
As such, in our opinion, the main benefit of adjunctive imaging lies in the assessment PV 
diameter  and  selection  of  the  appropriately  sized  cryoballoon  [26,37].  We  rely  on  the 
combination  of  pre-procedural  cardiac  magnetic  resonance  imaging  and  intra-procedural 
pulmonary  venography  and/or  intracardiac  echocardiography  to  define  pulmonary  venous 
anatomy and calibre. While venography is widely available and easy to perform, the use of 
intraprocedural  intracardiac  or  transesophageal  echocardiography  provides  a  supplemental 
assessment of PV occlusion through the use of colour flow doppler (CFD) imaging. Total 
occlusion  of  the  PV,  as  confirmed  by  CFD,  successfully  predicts  PVI  with  a  positive 
predictive value of 93-98%. Conversely, a negative predictive value for successful PVI of 92-
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100% was found in cases of persistent leak [30,38]. While it has been reported that procedure 
and fluoroscopy times can be reduced through the use of intracardiac echocardiography, the 
use  of  pre-  or  intraprocedural  imaging  has  not  been shown to  directly  affect  longer-term 
efficacy. As such, the use of pre-procedural or intraprocedural imaging are largely based upon 
cost, physician preference, and regional patterns of practice.                                   
Choosing a Cryoballoon: 23 mm vs. 28 mm                                                    
The current generation cryoballoon catheter is available in two sizes, i.e., with 23 or 28 mm 
diameter  balloons.  Some operators  prefer  exclusive  use of  the  larger  28 mm cryoballoon, 
whereas others have adopted a "toolbox" approach, with selective use of both the 23 mm and 
28 mm cryoballoon. Advocates for the single large cryoballoon approach highlight the high 
rate of PNP retrospectively observed with the 23 mm balloon, while proponents of the toolbox 
approach emphasize the potential for increased long-term efficacy [25,39].                      
The  premise  underlying  the  argument  for  exclusive  use of  the  larger  28  mm cryoballoon 
relates  to  the  relative  cryoballoon  to  PV  (CB-PV)  diameter  and  how  that  relationship 
influences the position of the resultant lesion. Early attempts to explain the excess incidence of 
PNP in association with 23 mm cryoballoon ablation (12.4% vs. 3.5% incidence with the 28 
mm cryoballoon) postulated that the deployment of relatively undersized balloons deep inside 
the PV could result in an increased risk of PNP [40]. In addition to minimising the physical 
distance  between the  cryoballoon and phrenic nerve,  CBA at  a  relatively  more distal  site 
within the RSPV results in a local environment more conducive to enhanced "cold" transfer to 
deeper tissue due to less convective heating of the balloon by atrial blood flow. As such, the 
"freeze" affected by a more distal cryoballoon position can be expected to result in deeper 
penetration of cryoenergy.  Consequently, some operators have suggested that the incidence of 
PNP can be minimized through the exclusive use of the 28-mm balloon [15,25,40]. However, 
re-examination  of the evidence  has  cast  doubt  on the validity  of  this  assertion.  While  the 
observed early excess of PNP with the 23 mm CBA cannot be denied, it is important to note  
that the exclusive use of larger balloons has not entirely eliminated this complication. "Over-
sizing" the balloon within the RSPV may result  in:  1) mechanical  distortion of the RSPV 
orifice with an even greater shortening of the relative distance between the cryoballoon and 
phrenic nerve, and 2) physical impingement of the phrenic nerve with resultant palsy [23].  
It may be reasonably argued that the critical factor in preventing PNP is the avoidance of distal 
CBA by insuring that the diameter of the cryoballoon exceeds the diameter of the vein. While 
Chun et al recommended a critical PV to cryoballoon ratio of 0.93 when using the 28 mm 
cryoballoon for septal PVs, the authors did not derive a comparable ratio for left-sided veins 
nor for the 23 mm balloon [40]. In this regard, recent studies by Vogt et al. and Nadji et al. 
have shown that the 23 mm cryoballoon can be safely used to treat PVs smaller than 18 to 20 
mm, respectively. Taken together, it appears that a CB-PV ratio of 0.9 may be appropriate for 
the 28 mm cryoballoon and that a CB-PV ratio of 0.8-0.85 may be preferable for the 23 mm 
balloon  [37,39].                                                
Our approach is to perform pre- and/or intra-procedural imaging to guide cryoballoon catheter 
selection. In general, when the PV diameter is less than 20 mm, we favour use of a 23 mm 
balloon.  With  larger  PV diameters  or  common  ostia,  we  resort  to  the  use  of  a  28  mm 
cryoballoon.
 
Balloon  Preparation  and  Ablation                                              
Once the appropriate  balloon is  selected,  the central  lumen is  flushed with saline prior to 
insertion  of  an  extra  support,  0.035-inch  J-tipped  guide  wire  (or  Achieve  catheter)  via  a 
Tuohy-Borst adaptor. Thereafter, the cryoballoon catheter is advanced through the FlexCath 
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into the left atrium where the guidewire (or Achieve catheter) is advanced into the targeted 
PV. We begin by targeting left-sided veins, working superiorly to inferiorly. Once the targeted 
vein is engaged with the guidewire, the cryoballoon is inflated in the body of the left atrium 
and advanced over the wire to the PV ostium. It is important to first inflate the balloon in the 
left  atrium rather  than  inside  the  PV in  order  to  avoid  distal  inflation,  which  potentially 
increases  the  risk  of  PV  damage,  phrenic  nerve  injury,  and  pulmonary  necrosis.  
PV  Occlusion  and  Lasting  Isolation                                        
To  achieve  lasting  PVI,  circumferential  tissue  contact  must  be  attained.  Failure  to  fully 
occlude the targeted PV during CBA will result in convective heating by intervening blood, 
which  reduces  the  efficiency  of  freezing  and  the  durability  of  the  lesion.            
Typically,  the assessment  of balloon occlusion is  performed through the injection  of  50% 
diluted contrast through the cryoballoon catheter's central lumen. (See Figure 1) In addition to 
providing confirmation of circumferential contact, which can be graded on a semi-quantitative 
scale  from 1 (negligible  occlusion with immediate  rapid outflow from the PV) to 4 (total 
occlusion with complete contrast retention), contrast injection also provides information on the 
exact position of the inflated balloon in relation to the PV–LA junction. Alternative methods 
for assessing the adequacy of balloon occlusion include color flow doppler echocardiography 
(i.e.  the absence  of  proximal  flow on either  transesophageal  or  intracardiac  echo)  as  well 
pulmonary  venous  pressure  assessment  (i.e.  the  transition  from a  left  atrial  to  pulmonary 
arterial  pressure  waveforms).  The  latter  two  methods  allow  for  assessment  of  dynamic 
occlusion  during  cryoablation  (i.e.  with  advanced  manoeuvres  such  as  the  "pull  down" 
technique), a period where confirmation of occlusion is not possible with contrast injection 
due to freezing of the central lumen of the cryoballoon catheter.
Figure 1: Cryoballoon Ablation of the Left Superior PV. Panel A. Cryoballoon (CB) ablation using a standard  
0.035-inch J-tipped guidewire. A grade three occlusion is demonstrated with the persistence of a small inferior 
leak (Arrow). Axial catheter rotation and slight relaxation of the forward pressure resulted in complete occlusion  
(not depicted). Of note a circular mapping catheter (CMC) is pictured on the left side of the image in the right  
superior  PV. Panel  B.  Cryoballoon ablation the Achieve  mapping catheter.  Complete (grade  4)  occlusion is 
demonstrated.  In  both  images  a  coronary  sinus  (CS)  catheter  is  pictured.                             
While every effort should be made to achieve optimal cryoballoon occlusion prior to ablation, 
it should be noted that a small degree of localized leak or delayed emptying of contrast (grade 
3 occlusion) may be acceptable,  since the onset of cryoablation is associated with balloon 
expansion,  which  may  improve  the  seal.                                    
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Management  of  Inadequate  Seal                                           
While  left-sided  veins  and  the  right  superior  vein  may  usually  be  directly  approached, 
variability  in  ostial  geometry  and  orientation  can  impede  adequate  circumferential 
cryoballoon-PV  contact.  In  this  case,  the  simplest  and  most  effective  manoeuvre  is  the 
combination of axial catheter rotation, catheter flexion, and/or repositioning of the guidewire 
within a different distal PV branch in order to reorient the balloon's axis. It is important to note 
that the current generation cryoballoon catheter relies on four equatorial anteriorly directed 
refrigerant jets to produce the lowest ablation temperatures in a large circular zone from the 
balloon equator  and extending a  few mm towards  its  distal  part.  As such,  should optimal 
occlusion only occur when the catheter shaft is misaligned compared to the axis of the PV, 
step-wise ablation should be performed from two different branches of the same vein to ensure 
that the entire circumferential  surface of the PV ostium is adequately ablated.              
In contrast  to the superior veins,  the inferior  PVs present particular  challenges  due to  the 
angulation of the transseptal sheath in relation to the PV ostia. In general, advancement of the 
cryoballoon catheter into the left atrium results in a cranial movement of the catheter. For the 
inferior veins, this results in a non-central alignment of the cryoballoon catheter in relation to 
the  PV  axis,  favouring  contact  along  the  superior  margin  of  the  PVs  at  the  expense  of 
suboptimal contact inferiorly. Similar to the other PVs, direct engagement should initially be 
attempted. Should optimal occlusion not be obtained through the above-mentioned torsional or 
angular manoeuvres, use of more sophisticated techniques may be required.[41] In patients 
with an early branching inferior PV, the "hockey stick" technique can be used to optimize 
tissue contact along the inferior PV circumference. After engaging the early branching inferior 
PV with the guidewire, a maximal bend is applied to the sheath in the superior-posterior LA. 
The sheath is then advanced, allowing the balloon to be propelled into the inferior part of the 
PV ostium. In patients with no or only a late branching inferior PV, the "pull-down" technique 
can  be  used  to  optimize  tissue  contact  along  the  inferior  PV  circumference.  With  this 
technique, the balloon is positioned parallel to the PV ostium to ensure optimal contact along 
the superior circumference of the PV. Cryoablation is then initiated regardless of the presence 
of an inferior leak. After approximately 60-90 seconds, when full N2O flow into the inner 
balloon is reached and the cryoballoon has adhered to the endocardium, the balloon and sheath 
are gently withdrawn or pulled down in order to seal the inferior margin of the PV. Of note, 
this manoeuvre must be performed with great care due to the potential risk of severe vascular 
damage associated with the application of excessive force. Lastly, in the case of an inferior 
RIPV ostium with a large persistent inferior leak precluding an effective "pull-down", the "big 
loop" technique can be used. For this technique, the sheath is maximally bent. While directed 
towards the lateral posterior LA, the guidewire is advanced along the posterior mitral annulus 
until the RIPV is reached. Thereafter, the sheath is positioned to guide the balloon over the 
wire  into  the  RIPV  ostium.                                            
Performing the Ablation Lesion and Intraprocedural Predictors of Success                 
When adequate  circumferential  contact  is  achieved,  contrast  material  is  flushed out of the 
catheter with saline, and a 240 second cryoablation is performed. Just prior to the onset of 
cryoablation,  we  apply  gentle  forward  pressure  on  the  cryoballoon  catheter  to  maximise 
contact between the cryoballoon and PV antra.                                               
Although trough-freezing temperatures below -80ºC are theoretically obtainable, in practice it 
is rare to achieve a trough freezing temperature below -60 to -70ºC. Cryoballoon temperatures 
are generally lower in the superior PVs when compared with inferior PVs, most likely due to 
passive warming of the proximal thermocouple by blood flow from the superior PVs [42]. A 
minimal cryoballoon temperature at the end of freezing of <-51°C has been reported to predict  
PVI with 100% specificity for both superior and inferior PVs.  In contrast, temperatures at 120 
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seconds of ≥ -36°C for superior PVs and ≥ -33°C for inferior PVs predicted ineffective PVI 
with 95% specificity (PPV 80%) and a 97% specificity (PPV 82%) respectively. As such, we 
interrupt cryoablation lesions that do not attain trough temperatures below -35°C for inferior 
PVs and below -40°C for superior PVs at 120 sec.                                           
Similarly, whenever possible, we attempt to record real-time PV signals during ablation. A 
recent study by Dorwarth et al. demonstrated that sustained PVI was associated with a shorter 
mean  time  to  conduction  block  (39  seconds)  when  compared  to  PVs  with  recovered  PV 
conduction (125 seconds) [43]. The authors identified a cut-off time of 83 seconds for the 
prediction of stable sustained PVI without reconduction (86% sensitivity and 97% specificity). 
While this information is promising, we do not rely solely on this criterion to determine the 
utility  (or  lack  thereof)  for  repeat  lesions  due  to  the  lack  of  longer-term follow-up  data. 
Moreover, in our experience with the Achieve catheter, real time recordings are obtainable in 
approximately 50% of PVs due to distal mapping catheter positioning (in order to achieve an 
adequate  cryoballoon  seal)  or  suboptimal  circumferential  mapping  catheter-vessel  wall 
contact.
Phrenic  Nerve  Monitoring                                                
Prior  to  ablation  of  right-sided PVs,  a  standard 5-Fr  quadripolar  catheter  is  placed in  the 
superior vena cava cranial to the right superior PV in order to pace the right phrenic nerve (10-
15 mA at 1.0-2.0 msec pulse width at  a cycle length of 1000 msec).  In addition to direct 
palpation  of  the  right  hemi-diaphragmatic  excursion,  it  is  our  practice  to  perform 
diaphragmatic  electromyography  (Figure 2).  We immediately  terminate  cryoablation  upon 
any perceived reduction in the strength of diaphragmatic contraction or a 30% reduction in the 
diaphragmatic  CMAP  amplitude.  Of  note,  if  the  procedure  is  performed  under  general 
anaesthesia, it is essential to discontinue use of paralytic agents at least 30 minutes prior to 
planned phrenic nerve pacing.
Confirmation of Isolation and the use of "Touch-ups"                                     
After ablation, as with all PVI procedures, we confirm the presence of PV entrance and exit 
block with a circular mapping catheter. In the rare instances when PVI was not achieved with 
the cryoballoon alone, we have targeted the few remaining left atrial–PV connections with the 
Freezor  Max  8-mm  tip  catheter  (Medtronic,  Minneapolis,  MN).  Although  some  centers 
aggressively pursue multiple cryoballoon applications until  PVI is achieved,  we prefer focal 
ablation "touch-ups" for PVs that prove initially difficult to isolate. Arguments for limiting the 
number of cryoballoon applications included the potential increased risk of phrenic nerve injury 
during right-sided ablation, and prolonged procedural time in the left atrium; both of which must 
be balanced against the increased costs of additional ablation catheters. It should be noted that 
the efficacy of PVI has not been shown to differ amongst the two approaches (>98% of patients 
achieve complete PVI with either  a cryoballoon-exclusive or "hybrid" cryoballoon-cryofocal 
approach).[11] As such, it remains a matter of physician preference.
Other  strategies  proposed  to  enhance  PVI  and  minimize  reconnection  include  serial 
cryoapplications based on the "freeze-thaw-freeze" principal. Alternatively, some authors have 
advocated  for  the  performance  of  sequential  engagement  and  cryoablation  using  multiple 
different  PV branches  in  order  to  create  sequential  overlapping  lesions.                  
End  of  the  Procedure                                
At the end of the procedure, the presence of entrance block is reconfirmed in all PVs prior to 
removal of the transseptal sheath(s). While it has become standard practice to include a post-
procedure observation period to monitor for acute reconnection after RF ablation, our sense is 
that such a waiting period is not necessary after CBA. In contrast to the relatively high rate of  
procedural  reconnection  observed  in  studies  of  RF-based  AF ablation  (up  to  50% in  some 
series), the rate of acute reconnection post CBA appears to be low. In studies employing waiting 
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periods of up to 60 minutes, the pooled rate of acute recurrence among the 749 treated PVs was 
<1%  [40,43,46-48].  Moreover,  in  contrast  to  RF-based  ablation,  the  use  of  adjunctive 
pharmacologic  agents  such  as  adenosine  and/or  isoproterenol  does  not  appear  to  provide 
additional  prognostic  information  in  patients  undergoing  CBA  [40,49,50].    
Figure  2: Configuration  of  surface  electrodes  (A)  and  corresponding  recordings  (B)  of  the  diaphragmatic 
compound motor action potential (CMAP) . Panel A depicts the surface electrode configuration used to record the 
diaphragmatic compound motor action potential (CMAP).  Electrodes are spaced 16 cm apart, one 5 cm above 
the xiphoid process and the second along the right costal margin.  Shown in Panel B are surface tracings from 
lead I and from the thoracic leads positioned to record diaphragmatic CMAPs.  The sweep speed is 100 mm/s.  
Note the stability of recorded CMAPs during right phrenic nerve pacing from the superior vena cava at 60 bpm.  
Reproduced with permission from Franceschi F, Dubuc M, Guerra PG, Khairy P. Phrenic nerve monitoring with  
diaphragmatic electromyography during cryoballoon ablation for atrial fibrillation: the first human application.  
Heart  Rhythm.  2011;8(7):1068-1071.  Copyright  ©  Elsevier,  2011.                               
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Persistent  AF                                              
 
While the acute success rate for paroxysmal AF is high (>98%), cryoballoon-based PVI alone 
for patients with persistent AF has been associated with high rates of arrhythmia recurrence 
(45% 1-year freedom from recurrent  AF).[11] Unlike patients with paroxysmal AF, catheter 
ablation  of  persistent  and  permanent  AF may require  more  extensive  ablation  beyond PVI 
[51,52].  In  this  patient  population,  the  left  atrial  substrate  plays  a  prominent  role  in  AF 
maintenance.  Staged ablation strategies  involving additional  linear  ablation and/or  complex 
fractionated  atrial  electrogram-based  (CFAE) ablation  have  yielded  superior  results  [51,53]. 
Recently, a small hypothesis-generating study by Mansour et al. investigated an approach of 
cryoballoon PVI combined with conventional irrigated-RF based substrate modification in 22 
participants with persistent AF.[54] The authors explored the utility of a step-wise approach 
beginning with cryoballoon-based PVI (22 participants) followed by CFAE ablation in those 
who had persistent or inducible AF (19 participants).  Thereafter,  linear ablation of the roof, 
mitral isthmus, and septum was performed if ablation did not terminate AF or if the arrhythmia 
changed to an atrial tachycardia or flutter (10 participants). After a mean follow-up of 6 months, 
the single procedure freedom from recurrent AF off AAD was a remarkable 86%. Based upon 
these results, the authors concluded that a combined cryoballoon and RF approach is feasible 
with favourable short-term maintenance of sinus rhythm. Prospective studies are required to 
determine whether the safety and efficacy of a hybrid cryoballoon approach merits adoption in 
clinical  practice.                                     
Conclusion
Cryoballoon-based catheter ablation is a safe and effective technique for PVI with high acute 
and medium-term efficacy rates when used for paroxysmal AF. The rate of complications with 
CBA is relatively low, with the exception of a disproportionately increased incidence of phrenic 
nerve palsy (the majority of which are transient). Whether further benefits of cryoablation are 
realized  will  depend  upon  operator  experience,  refinements  in  the  ablation  technique,  and 
evolutionary catheter development. Further studies, including direct comparison to conventional 
RF ablation are ongoing and will provide important insight into longer-term efficacy and safety.
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